SUMMARY A patient with systemic lupus erythematosus was first diagnosed after she had developed the Budd-Chiari syndrome. We believe that the Budd-Chiari syndrome was part of her tendency for thrombosis, induced by the presence of a lupus anticoagulant. The association between enhanced thrombosis and the lupus anticoagulant is discussed, and the need for prompt recognition and administration of anticoagulant therapy is emphasised.
Lupus anticoagulant (LAC) is an immunoglobulin which inhibits the conversion of prothrombin to thrombin. l 2 In spite of in vitro prolongation of the partial thromboplastin time (PIT), paradoxically, its presence has been associated with increased tendency to thromboembolic events and not with an increased bleeding tendencyi7
The anticoagulant is characteristically found in patients with systemic lupus erythematosus (SLE) but has also been observed in patients with other autoimmune diseases, drug induced SLE, malignancy, and no apparent underlying disease. [7] [8] [9] [10] [11] Among the reported thrombotic complications of LAC only one patient with the Budd-Chiari syndrome has been described. 12 This patient did not fulfil the accepted criteria of SLE. '3 Herein, we report a patient with SLE who developed the Budd-Chiari syndrome after a thrombotic occlusion of the inferior vena cava associated with the presence of a circulating anticoagulant.
Case report A 33 year old woman was admitted to our Accepted for publication 11 Over the following three years the patient was maintained on diuretics only. On her latest admission she had evidence of ascites and a distended periumbilical venous network. The liver was not enlarged and the spleen was palpable 4 cm below the costal margin. The relevant laboratory data were: anaemia with a haemoglobin of 11-2 g/dl (112 g/l), thrombocytopenia 92 000 platelets/mm3 (92x 109/l), erythrocyte sedimentation rate 100 mm/ 1st h, and slightly abnormal liver function tests, alkaline phosphatase 125 IU/ml (normal value <80 IU/ml), and serum aspartate transaminase 70 IU/ml (normal value <40 IU/ml). The serum concentrations of albumin and globulin were normal; protein electrophoresis, however, showed an increased fraction of gammaglobulin, 29-8% (normal up to 20%). IgA The presence of the lupus anticoagulant has also been associated with an increased incidence of thrombocytopenia, biological false positive VDRL tests, recurrent abortions, and possibly CNS and peripheral nerve involvement.6 11 16 Recent studies have suggested that the anticoagulant reacts with a phospholipid related antigen shared by clotting factors, platelets, cardiolipin, and other cell membranes.4 6 7 11 The reaction between the antibody and the antigen could result, on the one hand, in inhibition of clotting factors and thrombocytopenia, and on the other hand, in inhibition of prostacyclin production, release of procoagulant activity, and enhanced thrombss6 11 15 16 In view of the severe thrombotic complications in patients with the lupus anticoagulant it has been suggested that these patients should be treated with anticoagulants. " In fact, Pomeroy et 
